PrEP vs PEP: The Difference, Who They Are For and Why Timing Matters

PrEP uses antiretroviral medicine before exposure so that HIV is much less able to establish infection. Available products and dosing strategies differ by country, anatomy and population. HIV testing is required before starting because someone who already has HIV needs a full treatment regimen.

PrEP uses HIV medication to establish protective drug levels before an exposure occurs. In the United States, both oral and injectable PrEP options are available, and the appropriate choice depends on factors including the types of exposure, health history, medication considerations, and the ability to follow the required visit or dosing schedule. ?cite?turn124565search1?turn124565search5?

An HIV test is required before starting PrEP because PrEP is intended for people who do not have HIV. Continued HIV testing and routine follow-up are also needed while PrEP is used. PrEP works best when the chosen regimen is followed as prescribed; missing medication or appointments can reduce protection or complicate safe continuation.

PEP is a 28-day course of antiretroviral medicines started after a possible exposure. CDC states that it must begin within 72 hours and that earlier initiation is better. Baseline and follow-up HIV testing are part of care.

PEP is intended for urgent situations after a possible HIV exposure. It should be started as soon as possible and no later than 72 hours after the exposure; waiting for symptoms is not useful because early HIV infection may cause no recognizable symptoms. When PEP is indicated, evaluation should occur promptly rather than waiting several days to see how someone feels. ?cite?turn839850search11?turn839850search13?

PEP involves a prescribed course of HIV medication followed by HIV testing and clinical follow-up. Completing the regimen as directed matters, and a clinician can help manage side effects, medication interactions, or questions that arise during treatment.

PrEP can be appropriate for adults of different genders and orientations when there is ongoing HIV exposure risk. Eligibility should be based on actual exposure, partner viral suppression and current local guidance rather than identity stereotypes.

PrEP may be useful for people without HIV who could be exposed through anal or vaginal sex or through shared injection equipment. Examples include having a sexual partner with HIV whose viral suppression is unknown or not sustained, not consistently using condoms, having a recent STI, sharing injection equipment, or having needed PEP more than once. Current CDC guidance also supports discussing or prescribing PrEP for sexually active people who request it even when they do not report a specific risk factor. ?cite?turn124565search1?turn124565search5?

PrEP can be considered during changing circumstances rather than as a permanent identity or commitment. Someone may use it during a period of new partners, changing relationship agreements, or other potential exposures and later reassess with a clinician.

Anal or vaginal sex without effective prevention, needle sharing or certain occupational exposures may create a reason to ask about PEP. The risk depends on the source person’s HIV status and viral load, the activity and other factors. A clinician should assess rather than relying on an online percentage alone.

A possible HIV exposure generally involves blood, semen, vaginal fluid, rectal fluid, or another relevant body fluid contacting a mucous membrane, nonintact skin, or the bloodstream when HIV could be present. Examples can include a condom breaking during anal or vaginal sex, sharing needles or other injection equipment, or certain exposures during sexual assault. Whether PEP is recommended depends on the details and is assessed case by case when the source's HIV status is unknown. ?cite?turn839850search11?

Not every contact is considered a meaningful HIV exposure. Touching, intact-skin contact, and everyday contact do not transmit HIV, and oral sex carries little to no HIV transmission risk. However, a person's overall sexual encounter may include more than one type of exposure, so the full situation matters when deciding whether PEP is appropriate. ?cite?turn124565search3?turn124565search4?

Safe PrEP use includes HIV testing and, depending on the medicine, kidney, hepatitis or STI monitoring. PEP also includes follow-up HIV tests after the course. Missing follow-up can leave uncertainty about infection status.

Before starting PrEP, clinicians confirm that the person does not have HIV. Depending on the PrEP option and medical history, additional laboratory evaluation may be needed, and ongoing visits include repeat HIV testing and other monitoring appropriate to the medication. STI screening can be included because PrEP prevents HIV but does not prevent gonorrhea, chlamydia, syphilis, or other STIs. ?cite?turn124565search1?turn124565search5?

PEP also begins with HIV testing when feasible, but an indicated first dose should not be unnecessarily delayed while waiting for every test result. Follow-up HIV testing is needed after PEP because a test performed immediately after a new exposure cannot exclude infection from that exposure. Clinicians may also discuss STI testing, hepatitis status, pregnancy considerations, and future PrEP when appropriate. ?cite?turn839850search11?

They do not prevent gonorrhoea, chlamydia, syphilis, HPV or pregnancy. A complete sexual-health plan may use several prevention tools at the same time.

PrEP and PEP are specifically HIV prevention strategies. They do not prevent pregnancy and do not directly protect against infections such as gonorrhea, chlamydia, syphilis, herpes, or HPV. Condoms or other barriers, vaccination, contraception, and appropriate STI testing may therefore remain useful alongside HIV prevention medication. ?cite?turn124565search5?turn839850search15?

They are also not substitutes for HIV treatment in a person who already has HIV. HIV testing before PrEP and appropriate testing around PEP are important partly because established HIV infection requires a complete treatment regimen rather than prevention medication alone.